Seasonal influenza vaccination and the risk of infection with pandemic influenza: A possible illustration of nonspecific temporary immunity following infection

Eurosurveillance

Volumn 15, Issue 47, 2010, Pages

  Kelly, H ^a   Barry, S ^b   Laurie, K ^c   Mercer, G ^b  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b The Australian National University   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; HUMAN INTERFERON; INFLUENZA VACCINE; INTERFERON;

ADAPTIVE IMMUNITY; ARTICLE; CELLULAR IMMUNITY; CROSS PROTECTION; DISEASE TRANSMISSION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMORAL IMMUNITY; INFECTION RATE; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INNATE IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; RISK ASSESSMENT; RISK REDUCTION; SEASONAL VARIATION; VIRUS SHEDDING;

EID: 78649768784     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.15.47.19722-en     Document Type: Article

References (37)

1. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med.7(4):e1000258.
2. Kobinger GP, Meunier I, Patel A, Pillet S, Gren J, Stebner S, et al. Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J Infect Dis. 201(7):1000-1006.
3. Kelly H, Grant, K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 2009;14(31):pii=19288. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19288
4. Fielding J, Higgins N, Gregory J, Grant K, Catton M, Bergeri I, et al. Pandemic H1N1 influenza surveillance in Victoria, Australia, April - September, 2009. Euro Surveill. 2009;14(42):pii:19368. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19368
5. Tang JW, Tambyah PA, Wilder-Smith A, Puong KY, Shaw R, Barr IG, et al. Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis. 2010;16(5):874-876.
6. Carcione D, Giele C, Goggin LS, Kwan KS, Smith DW, Dows GK, et al. Association between 2009 seasonal influenza vaccine and influenza-like illness during the 2009 pandemic: preliminary results of a large household transmission study in Western Australia. Euro Surveill. 2010;15(28):pii=19616. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19616
7. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis. 2010;202(7):1011-1020.
8. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003:422(6930):428-433.
9. Tria F, Lässig M, Peliti L, Franz S. A minimal stochastic model for influenza evolution. J Stat Mech. 2005;P07008.
10. Omori R, Adams B, Sasaki A. Coexistence conditions for strains of influenza with immune cross-reaction. J Theor Biol. 2010;262(1):48-57.
11. Mercer GN, Barry SI, Kelly H. Modelling the association of seasonal influenza vaccination and the risk of infection with pandemic influenza. BMC Public Health. 2010; Forthcoming.
12. Minayev P, Ferguson NM. Improving the realism of deterministic multi-strain models: implications for modeling influenza A. J R Soc Interface. 2009;6(35):509-518.
13. Minayev P, Ferguson NM. Incorporating demographic stochasticity into multi-strain epidemic models: application to influenza A. J R Soc Interface. 2009;6(40):989-996.
14. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res. 2004;24(8):439-454.
15. Steel J, Staeheli P, Mubareka S, Garcia-Sastre A, Palese P, Lowen AC. Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol. 2010 84(1):21-26.
16. Van Hoeven N, Belser JA, Szretter KJ, Zeng H, Staeheli P, Swayne DE, et al. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol. 2009;83(7):2851-2861.
17. Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, et al. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol. 2009;83(8):3843-3851.
18. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One. 2009;4(5):e5538.
19. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal- Villán E, et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLos Pathog. 2009;6:e1000745.
20. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20):1945-1952.
21. Mathews JD, McBryde ES, McVernon J, Pallaghy PK, McCaw JM. Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-1919. BMC Infect Dis. 2010;10:128.
22. Slepushkin AN. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull World Health Organ. 1959;20(2-3):297-301.
23. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Crosssubtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis. 1985;151(1):81-88.
24. Linde A, Rotzen-Ostlund M, Zweygberg-Wirgart B, Rubinova S, Brytting M. Does viral interference affect spread of influenza? Euro Surveill. 2009;14(40):pii=19354. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19354
25. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007(2):CD001269.
26. Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol. 1982;116(2):212-227.
27. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-1108.
28. Skowronski DM, Janjua N, De Serres G, Hottes T et al. Analysis of the association between 2008-09 trivalent influenza vaccine (TIV) and pandemic A/H1N1 risk during the fall 2009. Options for the Control of Influenza VII; 2010; Hong Kong SAR, China. Available at http://www.controlinfluenza.com/abstracts/index.cfm?m=view&id=4405
29. Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ. 2009;339:b3928.
30. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales- Muniz C, Robles-Perez E, Gonzalez-Leon M, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet. 2009;374(9707):2072-2079.
31. Janjua NZ, Skowronski DM, Hottes TS, De Serres G, Crowcroft NS, Rosella LC. Seasonal vaccine and H1N1. Selection bias explains seasonal vaccine's protection. BMJ. 2009;339:b4972.
32. Janjua NZ, Skowronski DM, Hottes TS, De Serres G, Crowcroft NS, Rosella LC. Seasonal vaccine effectiveness against pandemic A/H1N1. Lancet. 2010;375(9717):801-802.
33. Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, Sherman SS, et al. Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis. 2009;49(12):1801-1810.
34. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado- Balaguer MD, Perez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010;28(47):7460-7467.
35. Centers for Disease Control and Prevention (CDC). Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(44):1241-1245.
36. Iuliano AD, Reed C, Guh A, Desai M, Dee DL, Kutty P, et al. Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis. 2009;49(12):1811-1820.
37. Lessler J, Reich NG, Cummings DA, Nair HP, Jordan HT, Thompson N. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med. 2009;361(27):2628-2636